trending Market Intelligence /marketintelligence/en/news-insights/trending/mxtpbi8vpgstrgrqplmt-g2 content esgSubNav
In This List

Intellipharmaceutics noncompliant with another Nasdaq listing rule

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Intellipharmaceutics noncompliant with another Nasdaq listing rule

Intellipharmaceutics International Inc. said it was no longer in compliance with Nasdaq's $2.5 million minimum stockholders' equity requirement for continued listing.

The Canadian pharmaceuticals company has until May 31 to remedy the situation.

Toronto-based Intellipharmaceutics is also in noncompliant with Nasdaq's minimum bid requirement listing rule and has until June 4 to regain compliance with that condition.